AIM (IIM) is engaged in the field of digital medicine, with an emphasis on advanced technologies and digital health. Upon completion of the offering, the partnership has already invested approximately 30% of the amount raised in two companies: GNX Data Systems, which develops an artificial intelligence system for smart and rapid analysis of genetic tests, and Biobeat Technologies, which develops wearable equipment – a watch and sticker for continuous monitoring of vital medical signs.
The partnership raised about NIS 32 million in a model of non-uniform offer – Book Building, for institutional and the general public, with the general partner and its controlling shareholder investing an additional amount of about NIS 8 million.
The participation units are expected to enter the TA-Growth, Global Bluetooth and TA-Technology indices at the beginning of March 2021.
Shuki Abramovich, Founder and Chairman of Infinity Inquiry Medical’s Investment Committee told FUNDER“Infinity International Medical IMED is proud to join the technology companies traded on the stock exchange. We are confident in the importance of connecting the high-tech world to the capital markets in Israel and expect significant success in the emerging moves. Digital health is groundbreaking and important at the national and business level.”
Meir Yehuda, director of the partnerships section in the IPO unit at the stock exchange, stated that: “The partnership has joined the 29 new companies listed on the stock exchange in 2020, including 19 high-tech companies and R&D partnerships. We believe that also in 2021, we will see high-tech companies and other R&D partnerships join the Tel Aviv Stock Exchange, so that the Tel Aviv Stock Exchange will be a bridge to the connection between Israeli high-tech and the capital market, for the benefit of investors and the entire Israeli economy. “